ZURICH, Switzerland — The latest Pfizer layoffs will see the drugmaker cut more than 200 jobs in Switzerland this year, shrinking its local workforce from about 300 people to roughly 70 as part of a restructuring of its Swiss unit. The cuts, disclosed by people familiar with the plan and first detailed in a Reuters report citing Bloomberg News, are part of a multiyear drive to restore profitability after the COVID-19 boom and are tied to a companywide savings goal of about $7.7 billion by the end of 2027, Dec. 10, 2025.
Pfizer layoffs in Switzerland slash local headcount.
According to the recent reporting, Pfizer’s Swiss business has been downgraded internally, leaving the country with a much smaller operation and a sharply reduced mandate. Rea Lal, appointed in September to lead the Swiss unit, now oversees a leaner organization after replacing former country head Sabine Bruckner, whose role shifted to a broader international post.
The Swiss cuts are the latest step in a rolling restructuring that has unfolded across Pfizer’s global footprint since its COVID-19 revenues began to fall. The new Pfizer layoffs add pressure on employees in a country that has long been a hub for multinational pharma, even as local rival Novartis also prepares to eliminate hundreds of roles in Switzerland by 2027.
Swiss move fits into $7.7 billion global savings plan.
Pfizer has repeatedly ratcheted up its cost-reduction ambitions over the past two years. In April, the company lifted its overall savings target to $7.7 billion through 2027, combining previously announced restructuring steps with an additional $1.2 billion in planned cuts focused on selling, informational, and administrative functions, as well as automation and artificial intelligence, according to earlier coverage in Fierce Pharma.
The push began in earnest in 2023, when Pfizer unveiled what it called an “enterprise-wide cost realignment program” designed to strip at least $3.5 billion a year from expenses by the end of 2024. That campaign was launched just after the company slashed its revenue forecast amid weaker-than-expected sales of its COVID-19 vaccine and antiviral treatment, as detailed in a Reuters story in October 2023 about the initial cost-cutting plan.
Previous Swiss cuts primed the ground for today’s announcement.
This latest round of Pfizer layoffs in Switzerland comes after a series of smaller trims tied to the integration of cancer specialist Seagen, which Pfizer acquired for $43 billion. In June 2024, nearly half of the workforce at Pfizer’s Zug site was told to leave or transfer internally, with 69 employees receiving termination notices and another 23 offered new positions, according to local outlet Zug4You.
Those earlier Swiss reductions were attributed to overlapping roles and “synergies” created when Pfizer folded Seagen’s European headquarters into its own structure. The newly announced cuts, which will shrink Swiss staff to about 70 people, suggest that the company now sees the country more as a streamlined commercial outpost than a fully fledged regional hub.
Pfizer layoffs echo a broader global retrenchment.
While the Swiss restructuring is striking in its severity, it is not an isolated event. Industry analysis by BioSpace estimates that Pfizer has already cut up to about 1,700 jobs worldwide since it first rolled out its cost realignment program, with layoffs in Ireland, the United Kingdom, multiple U.S. states, and other European markets.
The new Pfizer layoffs in Switzerland deepen that global trend and underscore how heavily the company is leaning on cost control to offset fading pandemic windfalls and looming patent expirations. For employees in Switzerland’s prized but increasingly competitive life-sciences sector, the message is clear: even longtime big-pharma employers are no longer immune from significant structural change.
